

Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30

LONOON and SALT LAKE CITY, Nov. 22, 2022 (GLOBE NEWSYMRE) - Renaytix pic. (NASDAQ. RNLD) (LSE. RENX) announces that it will report its first quarter fiscal year 2023 financial results on Wednesday, November 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Conference Call Details:

To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

About Remarks.

Remarks (35E RENX) (NASDAG: RNX.) is the global founder and leader in the new field of bioprognosis* To kickey health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX**, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to being make significant improvements in kidney disease prognosis, transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical care, patient stratification for drug clinical trials, and drug target discovery (viet transplant management, circical ca

Renalytix plc James McCullough, CEO

Stifel (Nominated Adviser, Joint Broker) Alex Price / Nicholas Moore

Tel: 020 7710 7600

www.renalytix.com Via Walbrook PR

Investec Bank plc (Joint Broker) Gary Clarence / Daniel Adams

Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

Walbrook PR Limited
Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 415-389-6400 or investors@renalytix.com

CapComm Partners Peter DeNardo